应激性高血糖比值(Stress Hyperglycemia Ratio, SHR)作为多种疾病发病和预后的一个重要生物标志物,在临床研究与实践中逐渐受到关注。SHR是一种用于评估急性疾病状态下患者血糖水平变化的指标。它通过比较入院时即刻血糖和糖化血红蛋白(HbA1c)来计算,以排除基线血糖水平的影响,反映了真实的急性高血糖状态,并可能通过减弱背景血糖状态的影响来更准确地识别应激性高血糖。已证明SHR是比动脉血气(arterial blood gas, ABG)更好的危重疾病预后预测因子。SHR作为一种相对简单的实验室指标,其在多种疾病中的应用表明其具有较高的临床价值。它不仅可以帮助识别应激性高血糖的患者,还可以用于评估患者的预后风险,从而为临床决策提供重要参考。本文将聚焦于应激性高血糖比值在多种疾病中的研究进展。Stress hyperglycemia ratio (SHR), as an important biomarker of pathogenesis and prognosis of many diseases, has been paid more and more attention in clinical research and practice. SHR is an indicator used to assess changes in blood glucose levels in patients with acute disease. It is calculated by comparing blood glucose and glycosylated hemoglobin (HbA1c) on admission to exclude the effect of baseline blood glucose levels. It reflects the true state of acute Hyperglycemia and may more accurately identify Stress Hyperglycemia by weakening the influence of background glucose status. SHR has been proved to be a better predictor of critical disease prognosis than arterial blood gas (ABG). As a relatively simple laboratory index, the application of SHR in many diseases shows that it has high clinical value. It can not only help identify patients with Stress Hyperglycemia, but also can be used to assess the prognosis risk of patients, thus providing an important reference for clinical decision-making. This article will focus on the research progress of Stress Hyperglycemia Ratio in many diseases.
暂无评论